Potentiation by a novel alkaloid glycoside adjuvant of a protective cytotoxic T cell immune response specific for a preerythrocytic malaria vaccine candidate antigen

Vaccine

Volumn 19, Issue 30, 2001, Pages 4153-4161

  Heal, Karen G ^a   Sheikh, Nadeem A ^b   Hollingdale, Michael R ^a   Morrow, W John W ^b   Taylor Robinson, Andrew W ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Alkaloid glycoside; Circumsporozoite protein; Malaria; Peptide delivery

Indexed keywords

ADJUVANT; CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MALARIA VACCINE; OVALBUMIN; PROTOZOAL PROTEIN; TOMATINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; DRUG POTENTIATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MALARIA; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PLASMODIUM BERGHEI; PROTOZOAN PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TOMATINE; VACCINATION;

EID: 0035919561     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00166-9     Document Type: Article

References (49)

1. Delivery systems for molecular vaccination
2. Novel aggregate structure adjuvants modulate proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice
3. The expanding universe of T-cell subsets: Th1, Th2 and more
4. Common west African HLA antigens are associated with protection from severe malaria
5. Molecular analysis of the association of HLA-B53 and resistance to severe malaria
6. T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic
7. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children
8. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein
9. HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers
10. + T cells and antibodies required for immunity to malaria sporozoites
11. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria
12. + cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria
13. + T lymphocytes is required for protective immunity against Plasmodium berghei
14. Attacking the infected hepatocyte
15. MHC class II restricted antigen presentation
16. Evaluation of novel aggregate structures as adjuvants: Composition, toxicity studies and humoral responses
17. + cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants
18. Vaccination against malaria: Targets, strategies and potentiation of immunity to blood stage parasites
19. Biology and immunology of sporozoite invasion of liver cells and exoerythrocytic development of malaria parasites
20. Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response
21. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
22. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria
23. Functional characterization of protective CD4+ T cell clones reactive to the murine malaria parasite Plasmodium chabaudi
24. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids
25. Th1 and Th2 CD4+ T cell clones specific for Plasmodium chabaudi but not for an unrelated antigen protect against blood stage P. chabaudi infection
26. Protective CD4+ T cell lines raised against Plasmodium chabaudi show characteristics of either Th1 or Th2 cells
27. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites
28. Sporozoite vaccine induces genetically restricted T-cell elimination of malaria from hepatocytes
29. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres
30. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon
31. Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures
32. + T cells
33. Interleukin-12 induction of interferon gamma-dependent protection against malaria
34. Recombinant human gamma interferon inhibits simian malaria
35. Sterile protection of monkeys against malaria after administration of interleukin-12
36. IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism
37. Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma-interferon and the parasite itself: Enhancement by exogenous tetrahydrobiopterin
38. Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity
39. Immune responses to liver stage parasites: Implications for vaccine development
40. Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine
41. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees
42. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides
43. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria
44. + T cell-mediated protective immunity against malaria
45. + T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity
46. Vaccines against intracellular infections requiring cellular immunity
47. Molecular basis of glycoalkaloid induced membrane disruption
48. Glycoalkaloids selectively permeabilize cholesterol containing membranes
49. Effect of alpha-tomatine and tomatidine on membrane potential of frog embryos and active transport of ions in frog skin